Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Leukocyte Biology|September 17, 2004
The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosingMaryrose Conklyn, Catharine Andresen, Paul Changelian, et al.
Current Opinion in Pharmacology|July 24, 2012
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseApostolos Kontzias, Alexander Kotlyar, Arian Laurence, et al.
European Journal of Pharmacology|February 5, 2008
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophiliaElizabeth Kudlacz, Maryrose Conklyn, Catharine Andresen, et al.
Current Opinion in Rheumatology|April 20, 2005
New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathwayJohn J O'Shea, Heiyoung Park, Marko Pesu, et al.
Arthritis Research & Therapy|February 1, 2008
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritisAnthony J Milici, Elizabeth M Kudlacz, Laurent Audoly, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 18, 2003
The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine modelsElizabeth Kudlacz, Bret Perry, Perry Sawyer, et al.
Journal of Leukocyte Biology|July 13, 2018
Translational and clinical advances in JAK-STAT biology: The present and future of jakinibsMassimo Gadina, Catrina Johnson, Daniella Schwartz, et al.
Molecular Immunology|June 29, 2004
Jak3 and the pathogenesis of severe combined immunodeficiencyJohn J O'Shea, Matthew Husa, Denise Li, et al.
Plos One|December 27, 2014
HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancerBrenda C O'Connell, Katie O'Callaghan, Bonnie Tillotson, et al.
JID Innovations : Skin Science From Molecules to Population Health|February 1, 2024
ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201Paul Changelian, Canxin Xu, Steve Mnich, et al.
Pageof 1